Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Cue Biopharma Inc | CUE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.13 | 04:54:53 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.13 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.3027 - 5.12 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 2.13 | USD |
Cue Biopharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 96.11M | 45.12M | - | 5.49M | -50.73M | -1.12 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Cue Biopharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CUE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.39 | 2.19 | 1.37 | 1.93 | 585,465 | 0.74 | 53.24% |
| 1 Month | 1.90 | 2.19 | 1.3027 | 1.78 | 356,910 | 0.23 | 12.11% |
| 3 Months | 2.31 | 2.58 | 1.3027 | 1.94 | 294,180 | -0.18 | -7.79% |
| 6 Months | 2.56 | 3.2491 | 1.3027 | 2.37 | 317,597 | -0.43 | -16.80% |
| 1 Year | 5.04 | 5.12 | 1.3027 | 2.94 | 347,192 | -2.91 | -57.74% |
| 3 Years | 11.26 | 18.42 | 1.3027 | 6.07 | 321,062 | -9.13 | -81.08% |
| 5 Years | 7.88 | 35.50 | 1.3027 | 9.43 | 285,572 | -5.75 | -72.97% |
Cue Biopharma Description
| Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The other products under pipeline are CUE-102, CUE-103, CUE-400, and CUE-401. |
